PDGFRB (Platelet Derived Growth Factor Receptor Beta)

This protocol is designed to evaluate the efficacy of an rhPDGF-enhanced advanced wound matrix for healing complex head and neck wounds post skin cancer excision that cannot heal by primary intention. This trial is registered at ClinicalTrials.gov ( NCT06634030 ).

Short-read sequencing cannot resolve whether co-occurring variants within a cancer gene are cis or trans , a distinction critical for clinical interpretation. Long-read nanopore sequencing addresses this gap through direct haplotype phasing, methylation detection, and complex structural variant resolution, confirming biallelic tumor suppressor inactivation and revealing compound cis oncogenic alleles with enhanced activity.

All Treg subsets attenuated daunorubicin cytotoxicity, whereas reduced sensitivity to gemcitabine was observed only in iTreg- and Tr1-containing cultures. These findings suggest that Treg cell subsets may directly promote stemness-associated and drug-tolerance-related features in K562 cells in vitro, supporting a tumor-promoting role within the leukemia microenvironment and warranting further validation in primary leukemia samples and in vivo models.

The in vivo experiment results confirmed excellent antitumor effect of the LpCZN-DOX. Therefore, the development of LpCZN-DOX will provide a novel strategy for achieving precise therapy in lung cancer.

Furthermore, we found that perivascular accumulation of MAPT/tau is an effective way to monitor peptide P140 treatment efficacy in GB and for prognosis of the patient evolution. Our findings validate P140 peptide treatment as a safe and specific strategy to halt GB progression and establish the clinical relevance of extracellular MAPT/tau as a biomarker for therapeutic success in GB.Abbreviations: ACTA2/ASMA: actin alpha 2, smooth muscle; BBB: blood-brain barrier; CMA: chaperone-mediated autophagy; CTLA4: cytotoxic T-lymphocyte associated protein 4; DAB: 3-3'diaminobenzidine; GB: glioblastoma; GBCPC: GB-conditioned pericyte; GSCs: glioblastoma stem cells; HSPA8/HSC70: heat shock protein family A (Hsp70) member 8; LAMP2A: lysosome associated membrane protein 2A; LI: lysosomal inhibitors; MAPT/tau: microtubule associated protein tau; NAc: N-acetylcysteine; PC: pericyte; PCGB: pericyte-glioblastoma coculture; PDGFRB: platelet derived growth factor receptor beta; ROS: Reactive oxygen species; SPARC: secreted protein acidic and cysteine rich; TME: tumor microenvironment; TNT: tunneling nanotubes.

Crucially, by identifying site-specific molecular markers, these discoveries pave the way for personalized medicine techniques and allow tumor-specific therapy tactics, such as targeting Central Carbon Metabolism in lung and skin metastases. This work provides actionable options for tumor-specific treatment and tailored interventions by highlighting new molecular candidates and signaling pathways for metastatic breast cancer.

Integrating our results with published datasets of AFX and PDS mutation profiles we observed a divergent distribution of alterations in genes signalling through angiogenic pathway (KDR, PDGFRB), DNA damage response (ATR), cellular migration/metastasis (DDR2, CDH1). These differences do not reach statistical significance, and histopathological evaluation remains the diagnostic gold standard, however, they offer valuable insights into the pathogenesis of these tumours.

Eleven genes differentially expressed (p≤0.05) in AAA lesions vs. normal aortas were not reported previously: upregulated: COL6A3, COL15A1, ICAM2, APOD, CIB and SERPINB6; downregulated: GJA1, SCNN1B, NPR1, ACTN1 and PLN. Remaining results confirmed previous reports regarding 21 genes differentially expressed in AAA. qRT-PCR results were in general in agreement with microarray results.

The patient achieved complete remission following the standard 7 + 3 induction chemotherapy regimen for AML with gemtuzumab ozogamicin. This case illustrates the diagnostic challenges posed by concomitant class-defining alterations in hematologic neoplasms and underscores the importance of integrated genomic assessment.

P2/3, N=87, Recruiting, Universita Degli Studi Di Milano Bicocca | Not yet recruiting --> Recruiting